52697 Incidence of Injection-Site Reactions With Dupilumab Treatment in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis

Robert Bissonnette

doi:10.1016/j.jaad.2024.07.947

52697 Incidence of Injection-Site Reactions With Dupilumab Treatment in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis

Robert Bissonnette

https://doi.org/10.1016/j.jaad.2024.07.947

Copy DOI

Export

Save

Cite

Journal: Journal of the American Academy of Dermatology

Publication Date: Sep 1, 2024

#Dupilumab Treatment #Atopic Dermatitis #5-year Extension #Open-Label Study #5-Year Study #Open-Label Extension Study #Open-Label Extension #Injection-site Reactions #Extension Study

Abstract
Full-Text
Similar Papers

Abstract

Listen

52697 Incidence of Injection-Site Reactions With Dupilumab Treatment in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of the American Academy of Dermatology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

52697 Incidence of Injection-Site Reactions With Dupilumab Treatment in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis